Cargando…

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development

Causality assessment is a critical step in establishing the diagnosis of drug induced liver injury (DILI) during drug development. DILI may resemble almost any type of liver disease, and often presents a serious challenge to clinical investigators and drug makers. The diagnosis of DILI is largely ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regev, Arie, Seeff, Leonard B., Merz, Michael, Ormarsdottir, Sif, Aithal, Guruprasad P., Gallivan, Jim, Watkins, Paul B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212150/ https://www.ncbi.nlm.nih.gov/pubmed/25352327 http://dx.doi.org/10.1007/s40264-014-0185-4

Ejemplares similares

A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT)
por: Tillmann, Hans L., et al.
Publicado: (2022)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)

A novel phenotype‐based drug‐induced liver injury causality assessment tool (DILI‐CAT) allows for signal confirmation in early drug development
por: Hermann, Richard P., et al.
Publicado: (2022)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

The DILI‐sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation
por: Watkins, Paul B.
Publicado: (2019)

Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score
por: Danjuma, Mohammed Ibn-Mas’ud, et al.
Publicado: (2020)

Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development
por: Roth, Sharin E., et al.
Publicado: (2019)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
por: Moreno-Torres, Marta, et al.
Publicado: (2022)

Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019
por: Teschke, Rolf
Publicado: (2019)

The Promise of AI for DILI Prediction
por: Vall, Andreu, et al.
Publicado: (2021)

A case report of a drug‐induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing
por: González‐Muñoz, Miguel, et al.
Publicado: (2020)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Landscape of DILI-related adverse drug reaction in China Mainland
por: Wang, Jiabo, et al.
Publicado: (2022)

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI
por: Woodhead, J L, et al.
Publicado: (2014)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021)

Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM)
por: Teschke, Rolf, et al.
Publicado: (2021)

Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method
por: Teschke, Rolf, et al.
Publicado: (2022)

KNIME workflow for retrieving causal drug and protein interactions, building networks, and performing topological enrichment analysis demonstrated by a DILI case study
por: Füzi, Barbara, et al.
Publicado: (2022)

Biomarkers in DILI: One More Step Forward
por: Robles-Díaz, Mercedes, et al.
Publicado: (2016)

Mechanistic Studies of Idiosyncratic DILI: Clinical Implications
por: Uetrecht, Jack
Publicado: (2019)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
por: Teschke, Rolf, et al.
Publicado: (2021)

Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
por: Tátrai, Péter, et al.
Publicado: (2022)

Drug-induced liver injury: recent advances in diagnosis and risk assessment
por: Kullak-Ublick, Gerd A, et al.
Publicado: (2017)

The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future
por: Watkins, Paul B., et al.
Publicado: (2014)

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI
por: Stern, Sydney, et al.
Publicado: (2023)

The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI)
por: Ghallab, Ahmed
Publicado: (2014)

Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure
por: Liu, Anika, et al.
Publicado: (2021)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

DILI( C ): An AI-Based Classifier to Search for Drug-Induced Liver Injury Literature
por: Rathee, Sanjay, et al.
Publicado: (2022)

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis
por: Teschke, Rolf, et al.
Publicado: (2020)

The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
por: Walker, Paul A., et al.
Publicado: (2020)

Prospective identification and causality evaluation of suspected adverse drug reactions in neonates
por: Roberts, Eve K., et al.
Publicado: (2020)

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
por: Segovia-Zafra, Antonio, et al.
Publicado: (2021)

Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
por: Zachou, Maria, et al.
Publicado: (2022)

Factors limiting immunization coverage in urban Dili, Timor-Leste
por: Amin, Ruhul, et al.
Publicado: (2013)

Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints
por: Liu, Xiaobin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_217v1ahkuc0hpmk5cefnea9d9o